Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 2 of the 7 sources its claims cite were checked for support.
Abstract
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in September 2020 and is rapidly spreading toward fixation. Using a variety of statistical and dynamic modeling approaches, we estimate that this variant has a 43 to 90% (range of 95% credible intervals, 38 to 130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine rollout, COVID-19 hospitalizations and deaths across England in the first 6 months of 2021 were projected to exceed those in 2020. VOC 202012/01 has spread globally and exhibits a similar transmission increase (59 to 74%) in Denmark, Switzerland, and the United States.
Overview
CoChat Summary
TL;DR
Using sequencing, mobility/contact data, and dynamic transmission models, the paper finds that SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01) spread substantially faster than prior lineages in England. The authors estimate it is 43 to 90% more transmissible, with no clear evidence of increased disease severity, but warn that faster spread would increase cases, hospitalizations, and the need for stronger control measures and faster vaccination.
Key findings
- In UK sequencing data, VOC 202012/01 had the highest relative population growth rate among 307 other lineages in the first 31 days after initial phylogenetic observation, and it continued to expand.
- A multinomial spline model estimated an increased growth rate of +0.104 day–1 relative to B.1.177, corresponding to a 77% increase in reproduction number R (95% CI, 73 to 81%) assuming a 5.5-day generation interval.
- Alternative analyses estimated R for VOC 202012/01 to be 43% higher (95% CI, 38 to 48%) from case-based regression, and 55% higher in Denmark, 74% higher in Switzerland, and 59% higher in the United States.
- The transmission model found no clear increase or decrease in severity, with odds ratios of 0.92 for hospitalization, 0.90 for critical illness, and 0.90 for death, but estimated transmissibility was 65% higher in the three most affected NHS regions and 82% higher across all seven regions.
Methods
- The study combined publicly available sequencing data from COG-UK, Pillar 2 testing data for S gene target failure, mobility data from Google Community Mobility, and social contact data from the CoMix survey, plus analogous sequence/RT-PCR data from Denmark, Switzerland, and the US.
- The authors used multinomial and binomial generalized linear mixed models, negative binomial state-space models, and an age- and region-structured deterministic compartmental transmission model fitted to multiple regional data streams, including deaths, hospital admissions, bed occupancy, PCR prevalence, seroprevalence, and VOC frequency.
- They compared five mechanistic hypotheses for the rapid spread, assessed model fit with deviance information criteria and short-term prediction, and ran scenario projections under varying NPIs and vaccination rollout rates.
Limitations
- The paper states that only a small number of intervention and vaccination scenarios were considered, and these should not be viewed as the only policy options.
- It states that the transmission model does not explicitly capture nursing home or hospital transmission, and regions were fit separately rather than jointly modeling between-region transmission.
- It notes uncertainty in model choice and parameter assumptions, including school-closure assumptions and NPI efficacy; these are limitations stated in the paper.
- Evident from the text: the severity analysis is based on early population-level data up to 24 December 2020, so delays from infection to hospitalization or death could obscure severity effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 2 Measuring the growth rate of VOC 202012/01. (A) Average relativized growth rate (i.e., a measure of variant fitness relative to other variants present during the 31 days after initial phylogenetic observation of a given variant) for all lineages in the COG-UK dataset, highlighting many lineages that have risen to prominence including B.1.177, the lineage with the highest relative abundance during the initial phylogenetic observation of VOC 202012/01. The shaded regions show conservative 95% rejection intervals; VOC 202012/01 is the first strain to exceed this threshold of faster relativized growth. Although many lineages exhibit above-average rates of growth, VOC 202012/01 has had the highest average relativized growth of any lineage in the history of COG-UK surveillance of SARS-COV-2. (B) Plotting all lineages’ relativized growth rates [ρ(t)] as a function of lineage age with conservative 95% rejection intervals highlights the significantly faster growth of VOC 202012/01 relative to other lineages at comparable times since their initial observation. Later declines in VOC and B.1.177 correspond to highly uncertain estimates of growth rates for data that are yet to be backfilled, so these declines in ρ(t) are sensitive to the processing of future sequences from recent dates (fig. S1). (C) Muller plots of the relative abundances of the major SARS-CoV-2 variants in the UK, based on a multinomial spline fit to COG-UK sequence data (Table 1 and table S1, separate-slopes multinomial spline model). A model extrapolation until 1 March 2021 is shown (shaded area). Minority variants are 440 circulating SARS-CoV-2 variants of low abundance. Specific colors represent the same lineages in (A) to (C). (D) Mean reproduction number over 7-day periods in 149 upper-tier local authorities of England (colored by the NHS England region they are within) plotted against the weekly proportion of Pillar 2 community SARS-CoV-2 tests with S gene target failure shows the spread of VOC 202012/01, a corresponding increase in the reproduction number in each local authority, and the eventual impact of targeted government restrictions from 20 December 2020. Testing data are shown for the week after the reproduction number estimates to account for delays from infection to test.](https://figures.cochat.ai/paper-figures/6a959b32b94b41a4aab77f4b47b25a40/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-2.jpg)
![Fig. 3 Comparison of possible biological mechanisms underlying the rapid spread of VOC 202012/01. Each row shows a different assumed mechanism. (A) Relative frequency of VOC 202012/01 (black line and ribbon respectively denote observed S gene target failure frequency with 95% binomial credible interval; purple line and ribbon respectively denote mean and 95% credible interval from model fit). (B) Posterior estimates (mean and 95% credible intervals) for relative odds of hospitalization (severe illness), relative odds of ICU admission (critical illness), relative odds of death (fatal illness), growth rate as a multiplicative factor per week [i.e., exp(7·∆r)], and the parameter that defines the hypothesized mechanism; all parameters are relative to those estimated for preexisting variants. (C to E) Illustrative model fits for the South East NHS England region: (C) fitted two-strain increased transmissibility model with VOC 202012/01 included; (D) fitted two-strain increased transmissibility model with VOC 202012/01 removed; (E) fitted single-strain model without emergence of VOC 202012/01. Black lines denote observed data; error bars denote the date range and 95% credible intervals for observed PCR prevalence and seroprevalence; colored lines and ribbons denote median and 95% credible intervals from model fit.](https://figures.cochat.ai/paper-figures/806d848e45ca40c19e0cc853e2b24dfc/estimated-transmissibility-and-impact-of-sars-cov-2-lineage-b-1-1-7-in-england-figure-3.jpg)

Verification
Claims the paper makes
2 Valid · 0 Not valid · 4 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we did not find substantial differences in social interactions between regions of high and low VOC 202012/01 prevalence, as measured by Google mobility (11) and social contact survey data (12) from September to December 2020 (Fig. 1, E and F).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
What the sources say
- Not matchedcites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Methods (Survey methodology) identify this as the CoMix social-contact survey, supporting the citation’s identification of the survey. But the Results (Participant characteristics) say the data reported here were collected on 24–27 March 2020; this paper does not establish that its reported data cover September–December 2020. The comparison between regions is presented as the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This yielded an estimated increase in R for VOC 202012/01 of 43% (95% CI, 38 to 48%), increasing to a 57% (95% CI, 52 to 62%) increase if the spline was not included (Table 1, models 4a and 4b).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants.”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Discussion Combining multiple behavioral and epidemiological data sources with statistical and dynamic modeling, we estimated that the SARS-CoV-2 variant VOC 202012/01 has a 43 to 90% (range of 95% CrIs, 38 to 130%) higher reproduction number than preexisting variants of SARS-CoV-2 in England, assuming no changes to the generation interval. On the basis of early population-level data, we were unable to identify whether the new variant is associated with higher disease severity. Theoretical considerations suggest that, in some cases, natural selection may favor reduced severity of disease in pathogens (23). For this to be true, however, the pathogen’s infectious period must be truncated by disabling symptoms or death often enough that a less-virulent mutant generates more secondary infections despite potentially being less transmissible per contact, to the extent that decreased virulence and decreased transmissibility are consequences of the same mutation (e.g., one that decreases viral load). It is far from clear that this condition holds for SARS-CoV-2, given substantial transmission before the onset of severe symptoms. Regardless, without strengthened controls, there is a clear risk that future epidemic waves may be larger—and hence associated with greater burden—than previous waves. The UK government initiated a third national lockdown on 5 January 2021 in response to the rapid spread of VOC 202012/01, including school closures. Educational settings are among the largest institutions linked to SARS-CoV-2 clusters that remained open during the November 2020 lockdown (24), which means that the enacted school and university closures may have substantially assisted in reducing the burden of COVID-19 in early 2021. The increase in transmission associated with VOC 202012/01 has crucial implications for vaccination. First, it means that prompt and efficient vaccine delivery and distribution are even more important to reduce the impact of the pandemic in the near future. Increased transmission resulting from VOC 202012/01 will raise the herd immunity threshold, so that the potential burden of SARS-CoV-2 is larger and higher vaccine coverage will be required to achieve herd immunity. It is therefore extremely concerning that VOC 202012/01 has spread to at least 114 countries globally (2). Although VOC 202012/01 was first identified in England, a rapidly spreading variant has also been detected in South Africa (25, 26), where there was a marked increase in transmission in late 2020. Another variant exhibiting immune escape has emerged in Brazil (27, 28). Thus, vaccination timelines will also be a crucial determinant of future burden in other countries where similar new variants are present. Second, there is a need to assess how VOC 202012/01 and other emerging lineages affect the efficacy of vaccines (29, 30). Vaccine developers may need to consider developing formulations with variant sequences, and they may want to initiate post-licensure studies to detect differences in efficacy between the preexisting and new variants. Licensing authorities may need to clarify abbreviated pathways to marketing for vaccines that involve altering strain formulation without any other changes to their composition. There are limitations to our analysis. We have considered a small number of intervention and vaccination scenarios, which should not be regarded as the only available options for policy-makers. Our transmission model does not explicitly capture nursing home or hospital transmission of SARS-CoV-2, and we fit the model to each region of England separately rather than pooling information across regions and explicitly modeling transmission between regions. There are also uncertainties in the choice of model used to generate these predictions, and the exact choice will yield differences in the measures needed to control the epidemic. We note that even without increased susceptibility of children to VOC 202012/01, the more efficient spread of the variant implies that the difficult societal decision of closing schools will be a key public health question for multiple countries in the months ahead. We only assess relative support in the data for the mechanistic hypotheses proposed, but there may be other plausible mechanisms driving the resurgence of cases that we did not consider, and we have not identified the specific combination of mechanisms driving the increased transmission of VOC 202012/01. We identify increased transmissibility as the most parsimonious mechanistic explanation for the higher growth rate of VOC 202012/01, but a longer infectious period also fits the data well (table S4) and is supported by longitudinal testing data (17). Our conclusions about school closures were based on the assumption that children had reduced susceptibility and infectiousness relative to adults (19), but the precise values of these parameters and the impact of school closures remain the subject of scientific debate (31). We based our assumptions about the efficacy of NPIs on the measured impact on mobility of previous national lockdowns in England, but the impact of policy options cannot be predicted with certainty. Despite these limitations, we found strong evidence that VOC 202012/01 is spreading substantially faster than preexisting SARS-CoV-2 variants. Our modeling analysis suggests that this difference could be explained by an overall higher infectiousness of VOC 202012/01, but not by a shorter generation time or immune escape alone. Further experimental work will provide insight into the biological mechanisms for our observations, but given our projections of a rapid rise in incidence from VOC 202012/01—and the detection of other novel and highly transmissible variants (25–28)—there is an urgent need to consider what new approaches may be required to sufficiently reduce the ongoing transmission of SARS-CoV-2.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the relative population growth rate of VOC 202012/01 in the first 31 days after its initial phylogenetic observation was higher than that of all 307 other lineages with enough observations to obtain reliable growth-rate estimates (Fig. 2A and fig. S1).”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Measuring the new variant’s growth rate
plainn = 150,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of COVID-19 cases attributable to VOC 202012/01 increased rapidly in all regions of England, following an initial expansion in the southeast (Fig. 1A)”
§ Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England > Characteristics of the new variant
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 43 claims and every source verdict.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom.”
From New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, viral variants of concern have emerged in the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50–55).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several emerging viral variants of concern have been identified that have mutations in the spike protein, including the B.1.1.7 variant (originating from the UK and which has eight spike mutations92), the B.1.351 variant (originating from South Africa) and the P.1 variant (originating from Brazil and which also contains multiple mutations in the spike protein and is spreading widely)57,93.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological studies suggest that it was approximately 50% more transmissible than previously circulating UK variants 191,197,198 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [198]
The cited source says what the claim attributes to it.
In the citing paper
“it has been previously reported that B.1.1.7 is associated with lower Ct values, corresponding to higher VLs 3”
From Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals (2021) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
Markov Processes: Characterization and Convergence
Ethier, S. N., & Kurtz, T. G. (1986) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316658 · Cited by 3,634
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
Advanced Bayesian Multilevel Modeling with the R Package brms
Bürkner, P.-C. (2018) · The R Journal · doi:10.32614/rj-2018-017 · Cited by 3,015 · cited 9×
“168) 67 (53-83) 120 (92-152) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE North West VOC vs.”
BackgroundMethodInfluentialSocial Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900 · cited 10×
“105) 43 (40-46) 72 (67-78) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London VOC vs.”
BackgroundInfluentialSelf-citationProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · cited 8×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundResultInfluentialEstimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Self-citationA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 10×
“068) 23 (18-28) 37 (29-46) UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE London B.”
BackgroundInfluential
Cited by
Items 2,101–2,200 of 2,327
Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19
Jones-Cifuentes, N. A., Peña-López, B. O., & Rincón‐Orozco, B. (2022) · Salud UIS · doi:10.18273/saluduis.54.e:22058
Pulling it all together: where do we go from here?
Beltz, L. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98809-4.00011-5
Rees, E. E., Avery, B. P., Carabin, H., Carson, C. A., Champredon, D., de Montigny, S., Dougherty, B., Nasri, B., & Ogden, N. H. (2022) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v48i10a04f
Mnguni, A. T., Schietekat, D., Ebrahim, N., et al. (2022) · medRxiv · doi:10.1101/2022.11.08.22282097
Pellis, L., Birrell, P., Blake, J., Hall, I., House, T., Overton, C. E., Scarabel, F., Stage, H. B., & Angelis, D. D. (2022) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/rssa.12984
“Another valuable difference between the two concepts that is worth clarifying, given its recent relevance, concerns the emergence of COVID-19 variants and potential assessment of their transmission advantage and increased severity (Challen et al., 2021; Davies et al., 2021; Nyberg et al., 2021).”
BackgroundWeirich, A., Wiesmueller, G. A., Hurraß, J., & Kossow, A. (2022) · Das Gesundheitswesen · doi:10.1055/a-1967-9855
“Die N501Y-Mutation, die sowohl bei der Alpha- als auch der Beta-Variante nachweisbar ist, erhöht die Bindungsaffinität zur ACE2-Rezeptor-Bindungsstelle und wird daher als Schlüsselfaktor für die höhere Übertragbarkeit angesehen [1, 14].”
BackgroundVariantes del Virus SARS-COV-2 futuro y retos
Andrés, U. M. D. S., & Michel, A. M. V. (2022) · Comité Iberoamericano de Ética y Bioética eBooks · doi:10.55209/ceiibro2.9
SARS-CoV-2’NİN SÜREGELEN EVRİMİ: PANDEMİNİN SONUNA NE KADAR YAKINIZ?
Kilbaş, E. P. K., & Altındiş, M. (2022) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH · doi:10.34084/bshr.1200144
Brinkmann, C., Gohl, P., Mack, D., Pfeifer, J., Fenés, M. P., Harzer, O., & Zöllner, B. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3960546
(2022) · Letters in Applied NanoBioScience · doi:10.33263/lianbs123.087 · Cited by 1
SARS-COV-2 ՎԱՐԱԿ. ԱՌՈՂՋԱՊԱՀԱԿԱՆ ՆՈՐ ՄԱՐՏԱՀՐԱՎԵՐ (ԱԿՆԱՐԿ)
Ղազարյան, Ա. Գ. (2022) · MEDICINE SCIENCE AND EDUCATION · doi:10.56936/18291775-2022.33-29
Ergenç, Z., Ergenç, H., Öztürk, A., Kaya, G., Ocak, Ö. K., & İnce, Ö. (2022) · Journal of Acute Disease · doi:10.4103/2221-6189.362815
COVID-19: How Effective Are the Repurposed Drugs and Novel Agents in Treating the Infection?
Suet-May, C., Sin-Yee, K., Jia-Qing, L., Pey-Wen, G., Singh, H. K. A. P. R., Zhi-Zheng, T. T., Foo, J. B., Hamzah, S. B., Sellappans, R., & Yow, H.-Y. (2022) · Sudan Journal of Medical Sciences · doi:10.18502/sjms.v17i4.12550
“7 (Alpha) UK (Sept 2020) 17 genetic mutations and 8 (N501Y, A570D, P681H, T716I, S982A, D1118H, Δ69-70 deletion, and Δ144 deletion) are in S protein [92] Approximately 50% enhanced transmissibility [19]; Death risk ratio of 1.”
SARS-CoV-2 variants: Evolution observed in a local hospital between 2020 and 2021
Matsumoto, G., Abe, N., Nakanishi, K., Noguchi, N., Fukuda, S., Shimada, M., & Kamioka, M. (2022) · Tenri Medical Bulletin · doi:10.12936/tenrikiyo.25-023
Chowdhury, S. R., Chakrabarty, S., Chakraborti, M., & Das, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85730-7.00009-6
Rapid System to Detect Variants of SARS-CoV-2 in Nasopharyngeal Swabs
Favaro, M., Zampini, P., Pistoia, E. S., Gaziano, R., Grelli, S., & Fontana, C. (2023) · Viruses · doi:10.3390/v15020353
“It rapidly became the predominant variant in circulation in the UK and became a variant of concern due to its increased transmissibility [31,32].”
Nunn, A., Morrissey, A., Crocker, A., Patterson, K. A., Stares, J., Smith, K., Gilbert, L., & Wilkinson, K. (2023) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v49i23a05f
The molecular basis of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
Al-Othman, N., Rabayaa, M., & Ghanim, M. A. (2022) · Palestinian medical and pharmaceutical journal/Palestinian medical & pharmaceutical journal · doi:10.59049/2790-0231.1094
Reichmuth, M. L., Hodcroft, E. B., & Althaus, C. L. (2023) · medRxiv · doi:10.1101/2023.03.13.23287198
adaPop: Bayesian inference of dependent population dynamics in coalescent models
Cappello, L., Kim, J., & Palacios, J. A. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010897
“This is frequently done by fitting logistic growth models to the sampling dates only [33, 34].”
SARS-CoV-2: Structure, Pathogenesis, and Diagnosis
Goverdhan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00002-6 · Cited by 2
Gaskell, K. M., Elkheir, N., Mirfendesky, M., Rampling, T., Marks, M., Houlihan, C. F., Lemonge, N., Bristowe, H., Aslam, S., Kyprianou, D., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284372
“(subsequently named Alpha) ranged between 43–100% more transmissible than the previously circulating wild type SARS-CoV-2 virus [1, 2].”
BackgroundSARS COV-2 is constantly mutating: A never-ending surge causing threat to mankind
Gupta, A., Gupta, G., Ansari, N., & Agarwal, L. (2023) · Cardiometry · doi:10.18137/cardiometry.2022.25.13691374
Estimating the contagiousness ratio between two viral strainsPreprint
Dojola, G. D. C. D., Mastrantonio, G., Cerutti, F., et al. (2023) · medRxiv · doi:10.1101/2023.04.27.23289192
Medical Perspective on COVID-19
Hosseini-Nezhad, P., Hosseini-Nezhad, S., & Hosseini-Nezhad, A. (2023) · Contributions to economics · doi:10.1007/978-3-031-27886-0_2 · Cited by 1
Sarvmeili, J. (2022) · مجله دانشگاه علوم پزشکی اراک · doi:10.32598/jams.25.3.6932.1
A critical appraisal of the toxicological aspects of COVID-19 and its vaccines
Νikolouzakis, Τ. Κ., Călina, D. C., Brooks, B. D., Docea, A. O., & Tsatsakis, A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00590-x
Liu, M., Chen, H., Li, J., Cai, W., Xie, H., Lan, G., & Zeng, X. (2023) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2023.0043 · Cited by 1
“Primary virus growth dynamics were analyzedbymeasuringp24antigenlevelsinthesupernatantat4, 7,10,14,17,21,and24daysaftercoculturedinfection(Fig.4A).”
Simulation of particle transmission in an emergency waiting hall and management proposalsPreprint
Zhang, X., Jia, N., Xu, Q., Wang, Z., Zhou, X., Tian, H., Sun, X., & Zhang, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3034520/v1
Al-Dalfi, A. H. O. H. (2023) · International Journal of Physiology Nutrition and Physical Education · doi:10.22271/journalofsport.2023.v8.i1f.2748
Sarkari, O.-B., Baghian, N., Yazdani, A., et al. (2023) · Iranian Red Crescent Medical Journal · doi:10.32592/ircmj.2023.25.4.2691
Perlman, S. M., & Denison, M. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00017-7 · Cited by 3
Zhang, X., Luo, H., Charlett, A., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4526539
Análise genômica de SARS-CoV-2 na cidade de São Caetano do Sul, São Paulo, Brasil
Sales, F. C. D. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-02082023-153216
Predicting subnational incidence of COVID-19 cases and deaths in EU countriesPreprint
Robert, A., Chapman, L. A. C., Grah, R., et al. (2023) · medRxiv · doi:10.1101/2023.08.11.23293400
Self-citationDrivers and impact of the early silent invasion of SARS-CoV-2 AlphaPreprint
Faucher, B., Sabbatini, C. E., Czuppon, P., et al. (2023) · medRxiv · doi:10.1101/2023.08.21.23293488
GİRAY, B. G., & AÇIK, G. G. (2023) · The European Research Journal · doi:10.18621/eurj.1341822
Khorattanakulchai, N., & Phoolcharoen, W. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.292
Comparison of the Prognosis and Mortality of Sars-Cov-2 Variants in Critically İll Patients
Bayrakçı, S. (2023) · Asian Journal of Research in Infectious Diseases · doi:10.9734/ajrid/2023/v14i3295
Cats – Revered and Reviled – and Associated Zoonoses: Killing You Softly with Feces and Fleas
Sing, A., & Berger, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-27164-9_23
Barua, A., Hridoy, M. W., Uddin, K. R., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4592228
Safety of SARS-CoV-2 test-to-stay in daycare: a regression discontinuity in time analysisPreprint
Dewald, F., Steger, G., Fish, I., et al. (2023) · medRxiv · doi:10.1101/2023.10.11.23296808
“All analyses were performed under a protocol approved by the institutional review board of the 175 Medical Faculty of the University of Cologne (21-1358).”
MethodMathematical and statistical modeling of infection and transmission dynamics of viral diseases
Magal, P., Demongeot, J., & Longe, O. B. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-3760-2
Nugrahapraja, H., Syahira, N. H., & Fauzi, A. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20237501005
“The Alpha variant is estimated to have a higher transmissibility rate of 43-90% than the SARS-CoV-2 that appeared early in the pandemic [16].”
BackgroundMethodKrall, P. (2023) · Research Square · doi:10.21203/rs.3.rs-3612018/v1
Tracking SARS-CoV-2 variants in Kurdistan Region of Iraq.
Mohamedsalih, P. M., Salih, K. J., Kareem, B. O., & Sabir, D. K. (2023) · ZANCO Journal of Pure and Applied Sciences · doi:10.21271/zjpas.35.5.12 · Cited by 1
Reproduction number projection for the COVID-19 pandemic
Benjamin, R. L. (2023) · Advances in Continuous and Discrete Models · doi:10.1186/s13662-023-03792-2
Zeng, Y. J., Xia, F., Guo, C., Hu, C., Li, Y., Wang, X., Wu, Q., Chen, Z., Lu, J., & Wang, Z. (2023) · Viruses · doi:10.3390/v15122394 · Cited by 1
“There are nine mutations in the S protein of the Beta variant (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G and A701V), including three mutations (K417N, E484K and N501Y) in the receptor-binding domain (RBD), with enhanced binding affinity for human ACE2 [16–18].”
BackgroundJang, Y.-A., Wu, H.-Y., Hsu, Y., Chen, Y., Chiou, H.-Y., Sytwu, H., Chen, W. J., & Tsou, H. (2023) · Preventive Medicine · doi:10.1016/j.ypmed.2023.107820
Ingelbeen, B., Cumbane, V., Mandlate, F., Barbé, B., Nhachungue, S. M., Cavele, N., Manhiça, C., Cubai, C., Nguenha, N. M. C., Lacroix, A., et al. (2023) · medRxiv · doi:10.1101/2023.12.22.23300474
“Nonetheless, transmission slowed when infection-induced seroprevalence (e.g., 11.2% in March 2021) was still lower than the herd immunity threshold anticipated from the Alpha variants’ reported transmissibility (13).”
BackgroundInfluentialA Mini Review of Newly Identified Omicron Sublineages
Kandati, D. R., Anusha, S., & Palem, C. (2023) · Archives of Case Reports · doi:10.29328/journal.acr.1001082
Therapeutic landscape of SARS-CoV-2
Pandey, V. P., Sharma, S., Singh, V., Yadav, B. K., & Pokharel, Y. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95545-4.00020-7
Epidemiología de la pandemia por COVID-19
Contreras, V., Sánchez Lerma, L., Gastelbondo-Pastrana, B., Rivero Herrera, R., & Máttar, S. (2023) · doi:10.21892/9786287515376.4
Inokuchi, T., HOMMA, T., Kitasato, Y., AKIYAMA, M., CHIKASUE, A., Nishii, Y., BAN, S., Adachi, T., SONEZAKI, A., Masuda, H., et al. (2023) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms7012003
Улюкин, И. М., Сечин, А. А., & Орлова, Е. С. (2024) · Вектор научной мысли · doi:10.58351/2949-2041.2024.8.3.004
Aganović, A., Cao, G., Kurnitski, J., & Wargocki, P. L. (2024) · Building and Environment · doi:10.1016/j.buildenv.2024.111494
Kurita, J., & Iwasaki, Y. (2024) · Online Journal of Public Health Informatics · doi:10.2196/44931 · Cited by 1
A parsimonious model explaining patterns in the Covid-19 eventPreprint
Krall, P., & Krall, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4258768/v1
Leite, G., Mehravar, S., Pimentel, M., Mathur, R., Melmed, G., Teagle, V., Barlow, G. M., & Rezaie, A. R. (2024) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2024.104097
Current Progress in Genomic and Genetic Research on Human Viral Diseases
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4833-2 · Cited by 1
SARS-CoV-2 epidemiology, kinetics, and evolution: a narrative reviewPreprint
Alizon, S., & Sofonea, M. T. (2024) · doi:10.31219/osf.io/etv85
Hempel, D., & Fleischmann, T. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23239-8.00024-9
Zaidi, I., Saleem, S. M., Vardha, J., Anjum, S., Chaudhary, S., Khayum, A., Shoib, S., & Nuguru, G. (2024) · Journal of Microbiology & Experimentation · doi:10.15406/jmen.2024.12.00415
Wáng, Y., Yu, H., Zhang, T., Sun, Z., Yao, W., Zhang, W., Chen, Q., Zhong, Y., Huang, Q., Wang, M., et al. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199400
“…T19R and T19I in the spike N-terminal domain; and N440K, K444N, Q493R and N532H in the spike receptor-binding domain), (Saifi et al., 2022) possibly contributing to increased transmission, virulence, mortality, and immune escape (Carabelli et al., 2023; Aziz et al., 2023; Davies et al., 2021).”
BackgroundDynamics Analysis of a COVID-19 Transmission Model Incorporating Vaccination and Failure
赵, 勇. (2024) · Advances in Applied Mathematics · doi:10.12677/aam.2024.135222
Li, Q., Ling, Y., Chen, G., & Ye, S. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111406
Zhang, X., Luo, H., Charlett, A., Angelis, D. D., Liu, W. Y., Vickerman, P. T., Woolhouse, M. E. J., & Wu, L. (2024) · BMC Global and Public Health · doi:10.1186/s44263-024-00069-y · Cited by 1
S-gene analysis: RT-PCR and Sanger sequencing applied to SARS-CoV-2 virus
Ishige, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00024-x
Modeling the Effect of Disease Characteristics on the Outcomes of Interventions
Lisitza, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-59072-6_15
Reflections on two years estimating effective reproduction numbers
Abbott, S., & Funk, S. (2022) · doi:10.59350/8apn9-8h048
Self-citationYang, J. E., Fan, H., Yang, A., Wang, W., Wan, X. H., Lin, F., Yang, D., Wu, J., Wang, K., Li, W., et al. (2024) · Vaccines · doi:10.3390/vaccines12070742
“The emergence of new SARS-CoV-2 variants of concern, such as Alpha/B.1.1.7 in the United Kingdom [1,21], Gamma/P.1 in Brazil and Japan [22], Beta/B.1.351 in South Africa [2], Delta/B.1.617.2 in India [23], and Omicron/B.1.1.529 in South Africa and Botswana in November 2021 [24], has raised worries…”
BackgroundInfluentialEftekhari, A., Baghian, N., Yoshany, N., et al. (2024) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_679_23
“[2,3] to serious complications and mortality around the globe, so that by April 2023, more than 760 million people were affected worldwide by this disease, and more than 7 million of those affected were in Iran.”
BackgroundMutational landscape and emerging variants of SARS-CoV-2
Hamid, S., Badar, M. S., Alam, M. M., Ali, S. A., Hassan, M. F., & Alam, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95374-0.00007-5
Ingelbeen, B., Cumbane, V., Mandlate, F., Barbé, B., Nhachungue, S., Cavele, N., Manhiça, C., Cubai, C., Nguenha, N. M. C., Lacroix, A., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003550
A modeling framework for the analysis of the SARS‐CoV2 transmission dynamics
Chatzilena, A., Demiris, N., & Kalogeropoulos, K. (2024) · Statistics in Medicine · doi:10.1002/sim.10195
“Then, we adjust these estimates taking into account the improvement of health infrastructures after the first few months of the pandemic and the emergence of more lethal and transmissible variants at the end of 2020.”
Swallow, B., Grier, J., & Panovska‐Griffiths, J. (2024) · medRxiv · doi:10.1101/2024.08.14.24311985
Escape imunológico da variante P.1 em paciente com evolução crítica e vacinação completa
de Brito, A. C., Dantas, N. M., Carbonell, R. C. C., Ferreira, A. I. C., Nakashima, F., Ticianeli, J. G., Lima, G. M., Asato, M. S., & Sequeira, B. J. (2024) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e15222.2024
“Tal patogenia, desde o início da pandemia, revela a possibilidade de surgimento de novas variantes do SARS-CoV-2 com maior transmissibilidade ou virulência (DAVIES NG, et al., 2021).”
BackgroundEstablishment of national standards of SARS-CoV-2 variants in Taiwan
Wu, M.-S., Chang, P.-C., Lin, P.-L., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38275
“Among these variants, VOCs received significant attention due to their potential for heightened fatality rates and the possibility of eluding prevailing detection modalities [16].”
BackgroundBayega, A., Reiling, S. J., Dubuc, I., et al. (2024) · medRxiv · doi:10.1101/2024.10.09.24313595
Stability and Hopf bifurcation of TB-COVID-19 coinfection model with impact of time delay
Verma, V. S., Kaushik, H., Singh, R. S., Jain, S., & Akgül, A. (2024) · SeMA Journal · doi:10.1007/s40324-024-00366-4
Overview of Infectious Diseases of Concern to Dental Practitioners: Airborne Pathogens
Majstorović, M., & Canares, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-64611-9_2
Extracorporeal Membrane Oxygenation for COVID-19 During the Delta and Omicron Waves in North America
Hickey, A. J., Greendyk, R. A., Cummings, M. J., Abrams, D. C., O’Donnell, M. R., Rackley, C. R., Barbaro, R. P., Brodie, D., & Agerstrand, C. L. (2024) · ASAIO Journal · doi:10.1097/mat.0000000000002334
Modelling plausible scenarios for the Omicron SARS-CoV-2 variant from early-stage surveillance
Banks, C. J., Colman, E. R., Wood, A. J., Doherty, T., & Kao, R. R. (2024) · Epidemics · doi:10.1016/j.epidem.2024.100800
Abuyadek, R. M., Mousa, M., Azazi, J. A., Romaithi, A. K. A., Selvaraj, F., AlSafar, H. S., Kaabi, N. A., & Hosani, F. I. A. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10124-6
“Alpha variant (B.1.1.7 and its descendent lineages) demonstrated over 50% increased transmissibility [3], while the Beta variant (B.1.351 and its descendent lineages) and Gamma variant (P.1 and its descendent lineages) showed the capacity to evade neutralizing antibodies [4].”
BackgroundInfluentialHow Did Latin America Face the SARS-CoV-2 Variants?
Jaspe, R. C., Zambrano, J. L., Loureiro, C. L., Rangel, H. R., & Pujol, F. H. (2024) · The Latin American studies book series · doi:10.1007/978-3-031-68419-7_7
Analysis of COVID-19 Infection Routes from the Viewpointof Fine Particle Technology
Nomura, T. (2021) · Journal of The Adhesion Society of Japan · doi:10.11618/adhesion.57.427
Phylogeogenomic analysis of the earliest reported sequences of SARS‐CoV‐2 from 161 countries
Laskar, R., Hoque, M., & Ali, S. (2024) · Apmis · doi:10.1111/apm.13499
Data-Driven Research for Understanding and Predicting Viral Epidemics and Evolution
Ito, J. (2024) · Uirusu · doi:10.2222/jsv.74.49
Quantifying microbial fitness in high-throughput experimentsPreprint
Fink, J. W., & Manhart, M. (2024) · eLife · doi:10.7554/elife.102635 · Cited by 2
Genomic and Epidemiological Surveillance of SARS-CoV-2 Epidemic in Northwestern Greece
Sakaloglou, P., Bozidis, P., Kourou, K., Kostoulas, C., Gouni, A., Tsaousi, E., Koumpouli, D., Argyropoulou, S., Oikonomidis, P., Peponi, H., et al. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69040026 · Cited by 3
“…mutational analysis of the SARS-CoV-2 genomes revealed that the S protein had undergone multiple mutations, indicating the potential for further accumulation and several combinations of mutations that may lead to the emergence of a variant with increased transmissibility and infectivity [29–31].”
Comparison of X-ray and CT Images of COVID-19 Caused by the Wild-Type and Alpha-Variant SARS-CoV-2
Tsuchida, C., Sakamaki, I., Hashimoto, N., et al. (2024) · Cureus · doi:10.7759/cureus.76493
“Moreover, mutations in the alpha variant of the spike protein may increase the efficiency of viral entry into cells and cause more severe lung damage [6].”
Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins
Fatima, I., Alshabrmi, F. M., Alkhayl, F. F. A., Qasim, M., Shafqat, A., Batool, S., Jawad, M. T., Qamar, M. T. U., & Rehman, A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673323348241208080419
Mathematical modelling for Covid-19
Kumar, R., Saxena, B., Shrivastava, R., & Bhardwaj, R. (2025) · AIP conference proceedings · doi:10.1063/5.0247445 · Cited by 3
Chatzilena, A., Hyams, C. J., Challen, R., Begier, E. M., Southern, J., Lahuerta, M., McGuinness, S., Clout, M., Campling, J., Oliver, J., et al. (2025) · medRxiv · doi:10.1101/2025.03.17.25324087
Nightlife and low immunity drove transmission of SARS-CoV-2 gamma in Luxembourg, 2021
Pires‐Afonso, Y., Bejko, D., Ernst, C., Huberty, C., Wienecke-Baldacchino, A. K., Berger, S., Herold, M., Walczak, C., Ogorzaly, L., Vergison, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-94323-4
The spread of the Delta variant in Catalonia during summer 2021: Modelling and interpretation
Steinegger, B., Burgio, G., Castioni, P., Granell, C., & Arenas, À. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102771
Guilbaud, R., Maiga, A. I., Ouédraogo, A., Sawadogo, Y., Niama, F. R., Mahamat, O. O., Toni, T. D., Kabo, A. K., Mayengué, P. I., Koukouikila-Koussounda, F., et al. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103334
Imtiaz, A., Akkam, A., AlThumali, L. H., AlHarthi, A. M., Porte, H. G., Alosaimi, W., AlAsmari, M. M. A., Salih, R. B. G., & Mitra, B. (2025) · BMC Pediatrics · doi:10.1186/s12887-025-05693-7
“The most dominant variants were the alpha variant with rates of transmissibility as high as 43–90% [11] and high mortality rates in the adult population [12, 13].”
Piazzese, C., Williams, S., Brentall, A., Kele, B., Bible, J. M., Harris, K. A., & Cutino-Moguel, T. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70402
SARS-CoV-2 Omicron: Genotyping, Mutational Analysis, and Characterization of Subvariants in Iran
Roozbehani, M., Keyvani, H., Tabibzadeh, A., Bokharaei‐Salim, F., & Mousavizadeh, L. (2025) · Infection Epidemiology and Microbiology · doi:10.61186/iem.11.2.123
Metadata
- Authors
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M., Atkins, K. E., & Edmunds, W. J.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- Selva Analytics LLC, Bozeman, MT, USA.
- KU Leuven (BE)
- Pennsylvania State University (US)
- Centre for Statistical Methodology and Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
- Corresponding author
- Davies, Nicholas G.
- ORCID
- Davies, Nicholas G.
- Abbott, Sam
- Barnard, Rosanna C.
- Jarvis, Christopher I.
- Kucharski, Adam J.
- Munday, James D.
- Pearson, Carl A. B.
- Russell, Timothy W.
- Tully, Damien C.
- Washburne, Alex D.
- Wenseleers, Tom
- Gimma, Amy
- Waites, William
- Wong, Kerry L. M.
- van Zandvoort, Kevin
- Silverman, Justin D.
- Diaz-Ordaz, Karla
- Keogh, Ruth
- Eggo, Rosalind M.
- Funk, Sebastian
- Jit, Mark
- Atkins, Katherine E.
- Edmunds, W. John
- Venue
- Science
- Published
- 2021-04-09
- Volume
- 372
- Issue
- 6538
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8128288
- OpenAlex
- W3134208712
- Semantic Scholar
- 34e9a0b4e42a4971a3a124c818045741c734fb9e
- Cited by
- 2,581
- References
- 58
- Citations by year
- 2026: 74 · 2025: 102 · 2024: 199 · 2023: 330 · 2022: 840 · 2021: 1028
- FWCI
- 215.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion, cc-by)
- Northumbria Research Link (Northumbria University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Kentucky
- Universität Bern
- Universitätsspital Basel
- National Institute for Health Research (NIHR200908)
- European Commission (101003688)
- CANDU Owners Group
- Hôpitaux Universitaires de Genève
- Eidgenössische Technische Hochschule Zürich
- Université de Sfax
- UKRI Research England (NA)
- National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR200929)
- United Kingdom Medical Research Council (MC_PC_19065)
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- SARS-CoV-2, B.1.1.7 variant, reproduction number, SARS-CoV-2 transmission, epidemic forecasting, COVID-19 containment measures, vaccine rollout, school closures, England
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Communicable Disease Control, England, Europe, Female, Humans, Infant, Male, Middle Aged, Models, Theoretical, Mutation, Severity of Illness Index, Socioeconomic Factors, United States, Viral Load, Basic Reproduction Number, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.